Cargando…
Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
Aberrant expression of the double homeobox 4 (DUX4) gene in skeletal muscle causes muscle deterioration and weakness in Facioscapulohumeral muscular dystrophy (FSHD). Since the presence of a permissive pLAM1 polyadenylation signal is essential for stabilization of DUX4 mRNA and translation of DUX4 p...
Autores principales: | Lu-Nguyen, Ngoc, Malerba, Alberto, Herath, Shan, Dickson, George, Popplewell, Linda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283208/ https://www.ncbi.nlm.nih.gov/pubmed/33987655 http://dx.doi.org/10.1093/hmg/ddab136 |
Ejemplares similares
-
Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression
por: Lu-Nguyen, Ngoc, et al.
Publicado: (2022) -
Therapeutic Strategies Targeting DUX4 in FSHD
por: Le Gall, Laura, et al.
Publicado: (2020) -
DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation
por: Banerji, Christopher R S, et al.
Publicado: (2020) -
Functional domains of the FSHD-associated DUX4 protein
por: Mitsuhashi, Hiroaki, et al.
Publicado: (2018) -
PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level
por: Banerji, Christopher R S, et al.
Publicado: (2019)